{"filing":{"accession_number":"0001193125-26-230852","cik":"0001374690","ticker":null,"company_name":"Larimar Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"lrmr-20260519.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526230852/lrmr-20260519.htm"},"classifications":[{"id":176,"accession_number":"0001193125-26-230852","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Larimar Therapeutics' 2026 Annual Meeting held on May 19, 2026. The filing reports final voting tallies for six proposals: election of three Class III directors (Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt), advisory approval of named executive officer compensation, advisory frequency vote on compensation (one year preferred), ratification of PricewaterhouseCoopers LLP as independent auditor, approval of an amendment to increase authorized common shares from 115 million to 215 million, and approval of an adjournment. All proposals passed with substantial majorities. This is material as it confirms board composition and shareholder approval of key governance and capital structure matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:20:08.915779+00:00","company_name":"Larimar Therapeutics, Inc.","ticker":null,"filing_date":"2026-05-19"}]}